Technical Analysis for NOVN - Novan, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 8.03 | -3.37% | -0.28 |
Earnings due: Aug 12
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical NOVN trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| BB Squeeze Started | Range Contraction | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | -3.37% | |
| Narrow Range Bar | Range Contraction | -4.40% | |
| Wide Bands | Range Expansion | -4.40% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 5% | about 8 hours ago |
| Down 3% | about 8 hours ago |
| Down 2 % | about 9 hours ago |
| Down 1% | about 9 hours ago |
| Fell Below Previous Day's Low | about 9 hours ago |
Get a Trading Sidekick!
- Earnings date: 08/12/2021
Novan, Inc. Description
Novan, Inc. is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs). The Company's formulation science enables it to further tune the release of nitric oxide when applied to the skin by using the combinations of inactive ingredients. It is developing SB204 for the treatment of acne vulgaris in Phase III. The Company is developing its product candidate, SB206, for the treatment of external genital and perianal warts in Phase II. It is developing SB208, an investigational topical anti-fungal for the treatment of fungal infections of the skin and nails. It is developing SB204 for the treatment of inflammatory skin diseases. Its pipeline also includes SB414, a topical cream product candidate.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Infectious Diseases Organ Systems Stage Pharmaceutical Dermatology Acne Chemical Entities Skin Diseases Fungal Infection Acne Vulgaris Fungal Infections Cutaneous Conditions Genital Wart Inflammatory Skin Diseases Late Stage Pharmaceutical Treatment Of Inflammatory Skin Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 25.9 |
| 52 Week Low | 3.011 |
| Average Volume | 4,798,579 |
| 200-Day Moving Average | 10.70 |
| 50-Day Moving Average | 10.03 |
| 20-Day Moving Average | 8.95 |
| 10-Day Moving Average | 8.43 |
| Average True Range | 0.77 |
| ADX | 11.61 |
| +DI | 24.65 |
| -DI | 27.47 |
| Chandelier Exit (Long, 3 ATRs) | 8.62 |
| Chandelier Exit (Short, 3 ATRs) | 10.19 |
| Upper Bollinger Bands | 10.21 |
| Lower Bollinger Band | 7.68 |
| Percent B (%b) | 0.14 |
| BandWidth | 28.32 |
| MACD Line | -0.60 |
| MACD Signal Line | -0.59 |
| MACD Histogram | -0.0111 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.60 | ||||
| Resistance 3 (R3) | 8.61 | 8.43 | 8.51 | ||
| Resistance 2 (R2) | 8.43 | 8.28 | 8.43 | 8.47 | |
| Resistance 1 (R1) | 8.23 | 8.20 | 8.14 | 8.22 | 8.44 |
| Pivot Point | 8.05 | 8.05 | 8.01 | 8.05 | 8.05 |
| Support 1 (S1) | 7.85 | 7.90 | 7.76 | 7.84 | 7.62 |
| Support 2 (S2) | 7.67 | 7.82 | 7.67 | 7.59 | |
| Support 3 (S3) | 7.47 | 7.67 | 7.56 | ||
| Support 4 (S4) | 7.46 |
